MORRISVILLET3D Therapeutics of Research Triangle Park has enlisted an all-star team of Alzheimer’s disease experts to guide the science behind its potential drugs for treating the affliction.

The creation of the new Scientific Advisory Board coincides with the company’s launch of a Phase 2 clinical trial of its leading drug candidate, T3D-959, an oral medication intended for patients with mild to moderate Alzheimer’s disease.

“These appointments come as the company enters a major new phase in its drug development lifecycle, the start of the Phase 2 PIONEER Study,” said John Didsbury, Ph.D., the company’s chief executive officer. “This transition brings new challenges and complexity where the collective knowledge and expertise of these Alzheimer’s disease clinical and research thought leaders can be brought to bear to help guide the company’s drug-development efforts.”

Appointed to the 10-member board are:

  • Roberta Brinton, Ph.D., director of the Center for Innovation in Brain Science and professor in the Departments of Pharmacology and Neurology in the College of Medicine at the University of Arizona in Tucson.
  • Roger Bullock, MB.BS, MRCPsych., chief medical officer at Oryzon Genomics of Barcelona, Spain.
  • Suzanne Craft, Ph.D., professor of medicine, director of the Alzheimer’s Disease Research Center and co-director of the Sticht Center for Healthy Aging and Alzheimer’s Prevention at the Wake Forest University School of Medicine in Winston-Salem.
  • Suzanne de la Monte, M.D., M.P.H., professor of pathology and laboratory medicine at Brown University in Providence, R.I.
  • Martin Farlow M.D., professor emeritus of neurology at Indiana University and associate co-director of the Indiana Alzheimer’s Disease Center in Indianapolis.
  • Michael Heneka, M.D., professor of clinical neuroscience and chair of the Department of Neurodegenerative Disease and Geriatric Psychiatry/Neurology at the University of Bonn Medical Center.
  • Thomas Montine, M.D., Ph.D., Stanford Medicine Endowed Professor in Pathology and chair of the Department of Pathology at Stanford University.
  • Marwan Sabbagh, M.D., FAAN., Camille and Larry Ruvo Endowed Chair for Brain Health and director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas.
  • Pierre Tariot, M.D., director of the Banner Alzheimer’s Institute and research professor of psychiatry, at the University of Arizona College of Medicine.
  • Michael Weiner, M.D., professor in residence in radiology and biomedical imaging, medicine, psychiatry and neurology at the University of California, San Francisco.

T3D is a privately held company founded in 2013. It received loans totaling $300,000 from the North Carolina Biotechnology Center to support its early work.

(c) North Carolina Biotechnology Center

RTP-based startup T3D offers hope to Alzheimer’s patients